Alnylam, with positive data on second gene-silencing drug, plans filing to FDA
LANE TURNER/THE BOSTON GLOBE
The company said it hopes to file with the Food and Drug Administration for accelerated approval of the drug, givosiran, likely by the end of the year.
No hay comentarios:
Publicar un comentario